Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Ganetespib
Synonyms
Therapy Description

Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ganetespib STA-9090 HSP90 Inhibitor 35 Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (PMID: 26244021).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 P223L TP53 V274F prostate cancer resistant Ganetespib Preclinical Actionable In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011). 26009011
TP53 R248Q Advanced Solid Tumor sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011). 26009011
FGFR2 - TACC3 Advanced Solid Tumor sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib treatment induced apoptosis, and inhibited Fgfr and Erk phosphorylation, cell proliferation, and tumor growth in a mouse cell line allograft model expressing FGFR2-TACC3 (PMID: 30067876). 30067876
TP53 R175H breast cancer sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PMID: 26009011). 26009011
TP53 R280K breast cancer sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011). 26009011
TP53 L194F breast cancer sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PMID: 26009011). 26009011
TP53 S241F ovarian cancer sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011). 26009011
BRAF V600E skin melanoma sensitive Ganetespib Preclinical - Cell line xenograft Actionable In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428). 24398428

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01200238 Phase II Ganetespib STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed USA 0
NCT01962948 Phase II Paclitaxel Ganetespib Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated USA 0
NCT01560416 Phase II Fulvestrant Ganetespib Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Completed USA 0
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 12
NCT02334319 Phase I Ganetespib Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated USA 0
NCT02389751 Phase I Carboplatin Paclitaxel Ganetespib A Study of Ganetespib in Combination With Chemoradiation Completed USA 0
NCT02637375 Phase I Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Withdrawn 0


Additional content available in CKB BOOST